Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma
Charles Herbaux(Centre Hospitalier Universitaire de Lille), Franck Morschhauser(Hôpital Claude Huriez), Hélène Demarquette(Ikerbasque), Élodie Drumez(Université de Lille), Adrien Chauchet(Centre Hospitalier Universitaire de Besançon), Roch Houot(Inserm), Éric Hermet(Centre Hospitalier Universitaire de Clermont-Ferrand), Anne Thiebaut‐Bertrand(Délégation Paris 7), Ibrahim Yakoub‐Agha(Inserm), Guillaume Manson(Hôpital Pontchaillou), Luc Mathieu Fornecker(Hôpital d'Hautepierre), Krimo Bouabdallah(Centre Hospitalier Universitaire de Bordeaux), Reza Tabrizi(Université de Bordeaux), Hervé Ghesquières(Université Claude Bernard Lyon 1), Hélène Doyen(Centre Hospitalier Universitaire de Tours), Loïc Ysebaert(Institut universitaire du cancer de Toulouse Oncopole), Pauline Brice(Hôpital Saint-Louis), Jordan Gauthier(Seattle Cancer Care Alliance), Julien Lazarovici(Institut Gustave Roussy), Eileen M. Boyle(BMW (Germany))
Cited by 217
Related Papers
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k
Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
|Annals of Oncology|2015|897
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2022|718